Drugs / OSU-2131
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06741072 | Jun 2026 → Jul 2027 expected | Epstein-Barr virus-associated lymphoproliferative disorder, end stage renal failure, post-transplant lymphoproliferative disease | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSU-2131 | “rh-Hsc70- BZLF1 peptide complex (OSU-2131)” NCT06741072 ↗ |
| Route | Subcutaneous | “receive OSU-2131 subcutaneously (SC)” NCT06741072 ↗ |